Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free BMRN Stock Alerts

BioMarin Pharmaceutical (BMRN) Financials

BioMarin Pharmaceutical logo
$51.81 -1.43 (-2.69%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$52.30 +0.49 (+0.95%)
As of 05/15/2026 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for BioMarin Pharmaceutical

Annual Income Statements for BioMarin Pharmaceutical

This table shows BioMarin Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -172 -630 -117 -77 -24 854 -64 142 168 427 349
Consolidated Net Income / (Loss)		 -172 -630 -117 -77 -24 854 -64 142 168 427 349
Net Income / (Loss) Continuing Operations		 -172 -630 -117 -77 -24 854 -64 142 168 427 349
Total Pre-Tax Income 		-155 -831 -36 -143 -95 -49 -75 150 189 542 482
Total Operating Income		 -111 -803 -15 -124 -100 -43 -82 161 186 484 409
Total Gross Profit		 738 907 1,072 1,176 1,345 1,336 1,376 1,593 1,887 2,274 2,504
Total Revenue		 890 1,117 1,314 1,491 1,704 1,860 1,846 2,096 2,419 2,854 3,221
Operating Revenue		 890 1,117 1,314 1,491 1,704 1,860 1,846 2,096 2,419 2,854 3,221
Total Cost of Revenue		 152 210 242 315 359 524 471 503 532 580 717
Operating Cost of Revenue		 152 210 242 315 359 524 471 503 532 580 717
Total Operating Expenses		 849 1,711 1,087 1,299 1,445 1,380 1,458 1,432 1,701 1,789 2,094
Selling, General & Admin Expense		 402 477 554 604 681 738 759 823 892 1,009 1,153
Research & Development Expense		 635 662 611 696 715 628 629 650 747 747 922
Amortization Expense		 -18 -27 46 49 74 67 70 67 62 43 19
Other Special Charges / (Income)		 -369 0.00 -125 -50 -25 -53 0.00 -108 0.00 -10 0.00
Total Other Income / (Expense), net		 -44 -28 -21 -19 5.65 -5.56 6.99 -11 2.79 58 73
Interest Expense		 38 39 43 44 23 29 15 16 17 13 11
Interest & Investment Income		 3.68 6.95 14 22 23 17 10 18 58 75 75
Other Income / (Expense), net		 -9.46 4.93 7.97 2.21 6.36 7.14 12 -13 -38 -4.67 9.00
Income Tax Expense		 17 -201 81 -65 -71 -903 -11 8.02 21 115 134
Basic Earnings per Share		 ($1.07) ($3.80) ($0.67) ($0.44) ($0.13) $4.72 ($0.35) $0.76 $0.89 $2.25 $1.82
Weighted Average Basic Shares Outstanding		 160.03M 165.99M 174.43M 177.06M 179.04M 180.80M 182.85M 185.27M 187.83M 190.03M 191.79M
Diluted Earnings per Share		 ($1.07) ($3.81) ($0.67) ($0.44) ($0.13) $4.50 ($0.35) $0.75 $0.87 $2.21 $1.80
Weighted Average Diluted Shares Outstanding		 160.03M 166.22M 174.43M 177.27M 179.04M 191.68M 182.85M 188.96M 191.60M 196.71M 197.39M
Weighted Average Basic & Diluted Shares Outstanding		 160.60M 165.80M 174.70M 175.50M 359.85M 181.83M 184.03M 186.53M 188.68M 190.78M 192.32M

Quarterly Income Statements for BioMarin Pharmaceutical

This table shows BioMarin Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 40 20 89 107 106 125 186 241 -31 -47 106
Consolidated Net Income / (Loss)		 40 20 89 107 106 125 186 241 -31 -47 106
Net Income / (Loss) Continuing Operations		 40 20 89 107 106 125 186 241 -31 -47 106
Total Pre-Tax Income 		42 19 106 132 134 170 238 298 -26 -27 141
Total Operating Income		 31 27 88 120 114 161 224 277 -47 -45 130
Total Gross Profit		 453 508 524 582 557 611 594 675 636 599 571
Total Revenue		 581 646 649 712 746 747 745 825 776 875 766
Operating Revenue		 581 646 649 712 746 747 745 825 776 875 766
Total Cost of Revenue		 128 138 125 130 188 136 152 150 140 276 195
Operating Cost of Revenue		 128 138 125 130 188 136 152 150 140 276 195
Total Operating Expenses		 423 481 435 461 443 450 370 398 683 643 442
Selling, General & Admin Expense		 216 260 226 263 253 267 206 232 268 446 258
Research & Development Expense		 191 206 205 184 185 174 159 161 409 192 179
Amortization Expense		 16 15 14 14 5.01 9.65 4.85 4.85 4.85 4.85 4.48
Total Other Income / (Expense), net		 11 -7.95 17 12 21 8.23 14 21 20 17 12
Interest Expense		 3.78 6.10 3.55 3.57 2.97 2.58 2.86 2.68 2.58 2.78 15
Interest & Investment Income		 16 18 19 20 18 18 19 19 18 19 23
Other Income / (Expense), net		 -0.82 -20 1.27 -4.53 5.46 -6.87 -1.95 4.83 5.09 1.03 3.96
Income Tax Expense		 1.29 -1.05 17 25 28 45 52 57 4.42 19 36
Basic Earnings per Share		 $0.21 $0.11 $0.47 $0.56 $0.56 $0.66 $0.97 $1.25 ($0.16) ($0.24) $0.55
Weighted Average Basic Shares Outstanding		 188.22M 187.83M 188.87M 190.11M 190.43M 190.03M 190.97M 191.91M 192.03M 191.79M 192.50M
Diluted Earnings per Share		 $0.21 $0.10 $0.46 $0.55 $0.55 $0.65 $0.95 $1.23 ($0.16) ($0.22) $0.54
Weighted Average Diluted Shares Outstanding		 191.17M 191.60M 199.26M 200.51M 197.15M 196.71M 196.47M 197.09M 192.03M 197.39M 197.67M
Weighted Average Basic & Diluted Shares Outstanding		 188.37M 188.68M 189.88M 190.38M 190.58M 190.78M 191.78M 192.01M 192.11M 192.32M 193.28M

Annual Cash Flow Statements for BioMarin Pharmaceutical

This table details how cash moves in and out of BioMarin Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -478 11 190 -104 -57 212 -62 137 31 188 369
Net Cash From Operating Activities		 -219 -228 -8.76 20 48 85 305 176 159 573 828
Net Cash From Continuing Operating Activities		 -219 -228 -8.76 20 48 85 305 176 159 573 828
Net Income / (Loss) Continuing Operations		 -172 -630 -117 -77 -24 854 -64 142 168 427 349
Consolidated Net Income / (Loss)		 -172 -630 -117 -77 -24 854 -64 142 168 427 349
Depreciation Expense		 47 97 88 96 105 105 108 102 104 96 80
Amortization Expense		 31 31 35 32 12 17 9.30 7.16 -5.04 -4.99 -2.18
Non-Cash Adjustments To Reconcile Net Income		 -67 720 24 79 133 220 193 72 229 215 647
Changes in Operating Assets and Liabilities, net		 -59 -445 -39 -109 -179 -1,110 58 -147 -337 -160 -245
Net Cash From Investing Activities		 -1,180 -484 -305 264 -31 -54 -366 -20 -111 136 -414
Net Cash From Continuing Investing Activities		 -1,180 -484 -305 264 -31 -54 -366 -20 -111 136 -414
Purchase of Property, Plant & Equipment		 -228 -148 -199 -145 -145 -114 -96 -121 -97 -85 -103
Acquisitions		 -538 -2.79 0.00 0.00 -18 -23 -24 -11 -11 -12 -293
Purchase of Investments		 -873 -700 -655 -635 -632 -530 -937 -612 -868 -410 -356
Sale and/or Maturity of Investments		 425 368 426 994 740 556 691 620 865 633 338
Other Investing Activities, net		 -375 -0.70 -1.75 50 24 58 -0.99 103 0.00 11 0.00
Net Cash From Financing Activities		 926 727 507 -388 -75 181 -0.05 -19 -19 -526 -42
Net Cash From Continuing Financing Activities		 926 727 507 -388 -75 181 -0.05 -19 -19 -526 -42
Repayment of Debt		 -2.59 -0.59 -0.03 -375 -5.09 -382 -3.44 -2.61 -12 -498 -0.89
Issuance of Common Equity		 951 787 61 67 32 72 49 69 69 49 14
Other Financing Activities, net		 -23 -59 -35 -81 -101 -45 -46 -85 -76 -78 -56
Effect of Exchange Rate Changes		 -5.07 -3.93 -3.23 -0.60 0.90 -1.15 -0.06 0.03 1.31 4.83 -2.52
Cash Interest Paid		 9.31 8.64 8.54 12 8.55 12 10 10 10 10 7.25
Cash Income Taxes Paid		 16 96 24 17 9.73 8.98 18 54 73 57 96

Quarterly Cash Flow Statements for BioMarin Pharmaceutical

This table details how cash moves in and out of BioMarin Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 91 -30 -8.13 225 -297 267 106 165 36 62 1,761
Net Cash From Operating Activities		 136 27 47 119 221 186 174 185 369 100 221
Net Cash From Continuing Operating Activities		 136 27 47 119 221 186 174 185 369 100 221
Net Income / (Loss) Continuing Operations		 40 20 89 107 106 125 186 241 -31 -47 106
Consolidated Net Income / (Loss)		 40 20 89 107 106 125 186 241 -31 -47 106
Depreciation Expense		 26 27 27 26 19 24 22 19 18 20 16
Amortization Expense		 -1.11 -1.46 -1.51 -1.19 -1.22 -1.07 -0.70 -0.70 -0.33 -0.45 5.63
Non-Cash Adjustments To Reconcile Net Income		 46 104 38 52 46 79 29 52 276 290 45
Changes in Operating Assets and Liabilities, net		 25 -122 -105 -66 51 -41 -62 -125 105 -163 48
Net Cash From Investing Activities		 -46 -65 -14 90 -16 76 -28 -13 -331 -42 726
Net Cash From Continuing Investing Activities		 -46 -65 -14 90 -16 76 -28 -13 -331 -42 726
Purchase of Property, Plant & Equipment		 -22 -29 -26 -21 -18 -20 -17 -17 -28 -41 -21
Purchase of Investments		 -283 -141 -122 -74 -157 -58 -89 -113 -111 -43 -26
Sale and/or Maturity of Investments		 261 113 132 186 161 155 78 118 99 43 767
Other Investing Activities, net		 - - 10 - 1.14 - 0.00 - - - 4.97
Net Cash From Financing Activities		 -0.79 11 -43 13 -499 2.86 -39 -4.60 -2.17 3.16 813
Net Cash From Continuing Financing Activities		 -0.79 11 -43 13 -499 2.86 -39 -4.60 -2.17 3.16 813
Repayment of Debt		 -0.61 -0.05 -0.04 -0.02 -498 -0.09 0.00 - - -0.89 -8.65
Issuance of Debt		 - - - - - - 0.00 - - - 850
Other Financing Activities, net		 -4.54 -3.92 -50 -17 -5.91 -4.91 -39 -12 -2.18 -2.70 -28
Effect of Exchange Rate Changes		 1.97 -3.65 1.93 3.30 -2.90 2.50 -1.42 -3.06 0.74 1.22 1.41
Cash Income Taxes Paid		 24 22 2.30 21 13 21 10 52 7.82 26 15

Annual Balance Sheets for BioMarin Pharmaceutical

This table presents BioMarin Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3,729 4,024 4,633 4,427 4,690 5,848 6,005 6,375 6,842 6,989 7,594
Total Current Assets		 1,090 1,422 2,207 2,056 1,942 2,342 2,274 2,751 2,956 3,232 3,953
Cash & Equivalents		 397 408 598 494 437 649 587 725 755 943 1,312
Short-Term Investments		 196 381 798 590 316 416 427 567 319 195 249
Accounts Receivable		 165 215 261 343 377 448 373 461 634 661 908
Inventories, net		 272 355 476 531 680 699 777 894 1,107 1,233 1,299
Other Current Assets		 60 62 74 98 131 130 110 105 141 202 186
Plant, Property, & Equipment, net		 704 799 897 949 1,011 1,032 1,035 1,073 1,066 1,043 953
Total Noncurrent Assets		 1,936 1,803 1,529 1,422 1,737 2,473 2,695 2,550 2,819 2,713 2,688
Long-Term Investments		 426 573 386 236 412 285 508 334 611 521 492
Goodwill		 197 197 197 197 197 196 196 196 196 196 196
Intangible Assets		 684 554 518 492 457 417 389 339 295 255 214
Noncurrent Deferred & Refundable Income Taxes		 220 447 399 461 549 1,432 1,450 1,505 1,546 1,489 1,509
Other Noncurrent Operating Assets		 409 33 30 37 122 142 152 176 172 251 277
Total Liabilities & Shareholders' Equity		 3,729 4,024 4,633 4,427 4,690 5,848 6,005 6,375 6,842 6,989 7,594
Total Liabilities		 1,329 1,257 1,824 1,459 1,568 1,742 1,739 1,772 1,890 1,331 1,507
Total Current Liabilities		 445 439 817 523 933 493 546 589 1,177 607 759
Accounts Payable		 393 371 402 437 571 493 498 573 683 607 759
Total Noncurrent Liabilities		 883 818 1,008 936 635 1,249 1,193 1,183 713 724 748
Long-Term Debt		 662 661 814 830 486 1,075 1,079 1,083 593 595 597
Other Noncurrent Operating Liabilities		 77 157 194 106 149 174 114 100 120 129 151
Total Equity & Noncontrolling Interests		 2,401 2,766 2,809 2,968 3,122 4,106 4,266 4,603 4,952 5,658 6,087
Total Preferred & Common Equity		 2,401 2,766 2,809 2,968 3,122 4,106 4,266 4,603 4,952 5,658 6,087
Total Common Equity		 2,401 2,766 2,809 2,968 3,122 4,106 4,266 4,603 4,952 5,658 6,087
Common Stock		 3,415 4,288 4,483 4,670 4,833 4,994 5,192 5,405 5,612 5,802 5,957
Retained Earnings		 -1,022 -1,521 -1,638 -1,694 -1,721 -862 -931 -789 -622 -195 154
Accumulated Other Comprehensive Income / (Loss)		 21 13 -23 5.27 20 -16 14 -3.87 -29 62 -13
Other Equity Adjustments		 -14 -14 -14 -13 -9.96 -9.84 -9.69 -8.86 -9.86 -11 -11

Quarterly Balance Sheets for BioMarin Pharmaceutical

This table presents BioMarin Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 6,264 6,434 6,563 6,758 6,873 7,067 6,851 7,147 7,456 7,615 8,591
Total Current Assets		 2,683 2,842 2,950 2,955 2,985 3,260 3,057 3,468 3,805 3,855 4,605
Cash & Equivalents		 762 580 694 785 747 972 675 1,049 1,214 1,250 2,222
Short-Term Investments		 512 572 477 340 300 252 255 224 218 228 0.00
Accounts Receivable		 420 598 610 572 637 691 778 739 856 790 904
Inventories, net		 839 919 976 1,032 1,138 1,184 1,179 1,275 1,340 1,382 1,273
Other Current Assets		 150 173 193 225 163 160 169 182 177 204 206
Plant, Property, & Equipment, net		 1,052 1,068 1,067 1,067 1,060 1,053 1,045 1,033 1,030 1,038 958
Total Noncurrent Assets		 2,530 2,523 2,546 2,736 2,827 2,755 2,749 2,646 2,621 2,722 3,028
Long-Term Investments		 372 341 386 548 621 557 562 507 509 513 0.00
Goodwill		 196 196 196 196 196 196 196 196 196 196 196
Intangible Assets		 354 326 310 302 280 266 261 247 240 233 205
Noncurrent Deferred & Refundable Income Taxes		 1,455 1,511 1,509 1,524 1,546 1,545 1,531 1,461 1,427 1,509 1,501
Other Noncurrent Operating Assets		 152 150 144 165 185 191 199 236 249 271 1,126
Total Liabilities & Shareholders' Equity		 6,264 6,434 6,563 6,758 6,873 7,067 6,851 7,147 7,456 7,615 8,591
Total Liabilities		 1,696 1,775 1,780 1,861 1,799 1,781 1,438 1,354 1,429 1,558 2,379
Total Current Liabilities		 521 598 597 1,163 1,088 1,067 716 628 684 798 793
Accounts Payable		 493 598 597 670 594 573 716 628 684 798 793
Total Noncurrent Liabilities		 1,175 1,176 1,183 698 711 713 722 725 745 760 1,586
Long-Term Debt		 1,082 1,084 1,085 593 594 594 595 596 596 597 1,430
Other Noncurrent Operating Liabilities		 92 92 98 105 117 119 128 130 149 163 155
Total Equity & Noncontrolling Interests		 4,569 4,659 4,783 4,897 5,074 5,286 5,413 5,793 6,027 6,057 6,212
Total Preferred & Common Equity		 4,569 4,659 4,783 4,897 5,074 5,286 5,413 5,793 6,027 6,057 6,212
Total Common Equity		 4,569 4,659 4,783 4,897 5,074 5,286 5,413 5,793 6,027 6,057 6,212
Common Stock		 5,336 5,418 5,494 5,543 5,619 5,697 5,740 5,794 5,852 5,901 5,967
Retained Earnings		 -789 -738 -682 -642 -533 -426 -320 -9.01 232 201 260
Accumulated Other Comprehensive Income / (Loss)		 31 -11 -19 6.26 -1.05 27 4.65 19 -45 -34 -4.24
Other Equity Adjustments		 -9.33 -9.95 -10 -10 -12 -12 -12 -11 -12 -11 -10

Annual Metrics And Ratios for BioMarin Pharmaceutical

This table displays calculated financial ratios and metrics derived from BioMarin Pharmaceutical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 18.77% 25.50% 17.62% 13.52% 14.27% 9.18% -0.76% 13.53% 15.42% 17.97% 12.87%
EBITDA Growth		 -225.97% -1,484.51% 117.38% -94.94% 292.83% 271.11% -45.50% 447.85% -3.79% 131.26% -13.16%
EBIT Growth		 -28.81% -564.51% 99.16% -1,702.66% 22.44% 61.43% -94.21% 309.25% 0.03% 224.99% -12.74%
NOPAT Growth		 -19.17% -625.76% 98.17% -740.30% 18.67% 56.76% -89.55% 364.32% 8.41% 130.99% -22.39%
Net Income Growth		 -28.24% -266.83% 81.43% 34.03% 69.11% 3,681.13% -107.50% 320.91% 18.43% 154.62% -18.26%
EPS Growth		 -16.30% -256.07% 82.41% 34.33% 70.45% 3,561.54% -107.78% 314.29% 16.00% 154.02% -18.55%
Operating Cash Flow Growth		 -211.69% -3.80% 96.16% 330.76% 138.83% 76.88% 256.75% -42.24% -9.46% 259.69% 44.54%
Free Cash Flow Firm Growth		 -312.03% 42.70% 77.95% -199.98% 21.41% -239.65% 90.66% 46.21% -110.44% 226.17% 83.79%
Invested Capital Growth		 85.38% 1.70% 5.70% 13.71% 9.38% 36.57% 1.07% 5.31% 6.79% 5.53% 0.81%
Revenue Q/Q Growth		 -0.16% 6.91% 4.64% -0.34% 6.32% -0.12% -0.12% 4.37% 4.70% 3.67% 4.11%
EBITDA Q/Q Growth		 77.54% -36.28% 390.33% -94.98% 330.09% -30.75% -28.66% 17.28% 14.12% 33.82% -28.81%
EBIT Q/Q Growth		 57.12% -30.40% 95.62% -560.24% 25.59% -3,343.79% -34.84% 39.58% 25.54% 44.27% -32.13%
NOPAT Q/Q Growth		 59.12% -31.17% 90.95% -351.99% 22.39% -3,896.32% -21.13% 68.77% 27.17% 43.73% -37.21%
Net Income Q/Q Growth		 44.62% -33.84% 25.15% 38.21% 43.92% 0.24% -690.82% 68.70% 14.03% 32.45% -32.96%
EPS Q/Q Growth		 46.77% -34.15% 22.99% 38.89% 48.00% 2.51% -305.88% 74.42% 11.54% 33.13% -32.58%
Operating Cash Flow Q/Q Growth		 -23.62% 22.37% 62.86% 238.87% 19.78% -45.31% 8.77% -2.44% 14.94% 38.13% -9.41%
Free Cash Flow Firm Q/Q Growth		 1.70% -24.82% 73.63% -85.22% 0.61% -10.36% 39.24% 44.82% 23.70% 139.28% -20.21%
Invested Capital Q/Q Growth		 9.15% 8.17% -4.40% 0.43% 1.06% 2.65% 0.65% 1.09% 1.03% 1.74% -0.67%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 82.92% 81.23% 81.59% 78.86% 78.91% 71.82% 74.52% 76.00% 78.01% 79.67% 77.73%
EBITDA Margin		 -4.75% -60.02% 8.87% 0.40% 1.36% 4.62% 2.54% 12.24% 10.21% 20.01% 15.39%
Operating Margin		 -12.44% -71.94% -1.12% -8.28% -5.90% -2.33% -4.46% 7.68% 7.68% 16.97% 12.71%
EBIT Margin		 -13.50% -71.50% -0.51% -8.14% -5.52% -1.95% -3.82% 7.04% 6.10% 16.80% 12.99%
Profit (Net Income) Margin		 -19.31% -56.43% -8.91% -5.18% -1.40% 45.90% -3.47% 6.75% 6.93% 14.96% 10.83%
Tax Burden Percent		 111.04% 75.83% 326.25% 54.11% 25.15% -1,743.02% 85.04% 94.64% 88.91% 78.79% 72.31%
Interest Burden Percent		 128.76% 104.08% 533.06% 117.63% 100.76% 134.99% 106.89% 101.40% 127.79% 112.97% 115.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.36% 11.09% 21.21% 27.69%
Return on Invested Capital (ROIC)		 -4.80% -26.58% -0.47% -3.59% -2.62% -0.92% -1.50% 3.83% 3.92% 8.53% 6.42%
ROIC Less NNEP Spread (ROIC-NNEP)		 22.17% -12.09% 17.53% -5.52% -15.50% -299.02% 0.43% 6.18% 3.48% 3.07% 2.23%
Return on Net Nonoperating Assets (RNNOA)		 -3.95% 2.19% -3.73% 0.92% 1.84% 24.55% -0.03% -0.64% -0.41% -0.48% -0.48%
Return on Equity (ROE)		 -8.75% -24.39% -4.20% -2.67% -0.78% 23.63% -1.53% 3.19% 3.51% 8.05% 5.94%
Cash Return on Invested Capital (CROIC)		 -64.63% -28.27% -6.01% -16.42% -11.58% -31.83% -2.56% -1.34% -2.65% 3.15% 5.61%
Operating Return on Assets (OROA)		 -3.87% -20.60% -0.16% -2.68% -2.06% -0.69% -1.19% 2.38% 2.23% 6.93% 5.74%
Return on Assets (ROA)		 -5.54% -16.26% -2.70% -1.70% -0.52% 16.21% -1.08% 2.29% 2.54% 6.17% 4.79%
Return on Common Equity (ROCE)		 -8.75% -24.39% -4.20% -2.67% -0.78% 23.63% -1.53% 3.19% 3.51% 8.05% 5.94%
Return on Equity Simple (ROE_SIMPLE)		 -7.16% -22.78% -4.17% -2.60% -0.76% 20.80% -1.50% 3.08% 3.39% 7.54% 0.00%
Net Operating Profit after Tax (NOPAT)		 -77 -562 -10 -86 -70 -30 -58 152 165 382 296
NOPAT Margin		 -8.71% -50.36% -0.78% -5.80% -4.13% -1.63% -3.12% 7.27% 6.83% 13.37% 9.19%
Net Nonoperating Expense Percent (NNEP)		 -26.97% -14.49% -18.00% 1.93% 12.88% 298.10% -1.92% -2.34% 0.44% 5.46% 4.19%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 2.67% 2.74% 6.10% 4.43%
Cost of Revenue to Revenue		 17.08% 18.77% 18.41% 21.14% 21.09% 28.18% 25.48% 24.00% 21.99% 20.33% 22.27%
SG&A Expenses to Revenue		 45.20% 42.67% 42.20% 40.53% 39.96% 39.65% 41.13% 39.28% 36.89% 35.36% 35.79%
R&D to Revenue		 71.33% 59.27% 46.49% 46.70% 41.96% 33.76% 34.06% 30.99% 30.87% 26.18% 28.62%
Operating Expenses to Revenue		 95.36% 153.17% 82.71% 87.14% 84.80% 74.16% 78.98% 68.32% 70.33% 62.70% 65.02%
Earnings before Interest and Taxes (EBIT)		 -120 -799 -6.73 -121 -94 -36 -70 148 148 480 418
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -670 117 5.90 23 86 47 257 247 571 496
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.04 5.15 5.58 5.11 4.86 3.88 3.80 4.18 3.67 2.21 1.88
Price to Tangible Book Value (P/TBV)		 11.12 7.07 7.48 6.65 6.15 4.56 4.41 4.73 4.07 2.41 2.01
Price to Revenue (P/Rev)		 18.98 12.76 11.92 10.17 8.91 8.56 8.79 9.18 7.51 4.39 3.54
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 18.64 0.00 135.87 108.34 29.35 32.72
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 5.37% 0.00% 0.74% 0.92% 3.41% 3.06%
Enterprise Value to Invested Capital (EV/IC)		 7.91 6.38 6.70 5.76 5.30 4.08 4.09 4.59 4.03 2.50 2.15
Enterprise Value to Revenue (EV/Rev)		 18.64 12.19 11.50 9.90 8.73 8.41 8.57 8.93 7.26 4.02 3.09
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 129.66 2,503.08 642.01 181.99 337.84 72.89 71.14 20.08 20.09
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 126.82 119.03 23.90 23.80
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 122.79 106.34 30.05 33.64
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 730.31 308.10 183.24 51.97 106.35 110.29 20.01 12.03
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 81.35 38.47
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.30 0.26 0.44 0.31 0.27 0.26 0.26 0.24 0.22 0.11 0.10
Long-Term Debt to Equity		 0.28 0.24 0.29 0.28 0.16 0.26 0.25 0.24 0.12 0.11 0.10
Financial Leverage		 -0.18 -0.18 -0.21 -0.17 -0.12 -0.08 -0.08 -0.10 -0.12 -0.16 -0.21
Leverage Ratio		 1.58 1.50 1.55 1.57 1.50 1.46 1.42 1.40 1.38 1.30 1.24
Compound Leverage Factor		 2.03 1.56 8.28 1.84 1.51 1.97 1.51 1.42 1.77 1.47 1.43
Debt to Total Capital		 22.95% 20.87% 30.42% 23.59% 21.36% 20.75% 20.90% 19.27% 18.00% 9.52% 8.93%
Short-Term Debt to Total Capital		 1.70% 1.97% 10.27% 2.21% 9.11% 0.00% 0.89% 0.28% 8.18% 0.00% 0.00%
Long-Term Debt to Total Capital		 21.25% 18.90% 20.15% 21.38% 12.25% 20.75% 20.01% 18.99% 9.82% 9.52% 8.93%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 77.05% 79.13% 69.58% 76.41% 78.64% 79.25% 79.10% 80.73% 82.00% 90.48% 91.07%
Debt to EBITDA		 -16.91 -1.09 10.54 155.42 36.62 12.51 24.06 4.28 4.40 1.04 1.20
Net Debt to EBITDA		 7.16 0.94 -4.75 -68.49 -13.72 -3.21 -8.42 -2.05 -2.42 -1.86 -2.94
Long-Term Debt to EBITDA		 -15.65 -0.99 6.98 140.84 20.99 12.51 23.04 4.22 2.40 1.04 1.20
Debt to NOPAT		 -9.23 -1.30 -119.35 -10.60 -12.06 -35.36 -19.56 7.21 6.58 1.56 2.02
Net Debt to NOPAT		 3.91 1.13 53.80 4.67 4.52 9.07 6.84 -3.46 -3.62 -2.79 -4.92
Long-Term Debt to NOPAT		 -8.55 -1.17 -79.06 -9.60 -6.91 -35.36 -18.72 7.11 3.59 1.56 2.02
Altman Z-Score		 7.59 6.19 5.29 6.36 5.85 5.95 5.99 7.15 6.38 6.69 5.68
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.45 3.24 2.70 3.93 2.08 4.76 4.16 4.67 2.51 5.33 5.21
Quick Ratio		 1.70 2.29 2.03 2.73 1.21 3.07 2.54 2.98 1.45 2.96 3.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1,044 -598 -132 -396 -311 -1,056 -99 -53 -112 141 259
Operating Cash Flow to CapEx		 -96.42% -153.55% -4.40% 13.97% 33.28% 74.68% 318.63% 145.42% 164.71% 670.59% 803.58%
Free Cash Flow to Firm to Interest Expense		 -27.29 -15.14 -3.09 -9.06 -13.25 -36.03 -6.43 -3.32 -6.44 11.12 23.76
Operating Cash Flow to Interest Expense		 -5.74 -5.77 -0.21 0.46 2.06 2.91 19.86 11.01 9.19 45.23 75.97
Operating Cash Flow Less CapEx to Interest Expense		 -11.69 -9.52 -4.87 -2.85 -4.12 -0.99 13.62 3.44 3.61 38.48 66.52
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.29 0.29 0.30 0.33 0.37 0.35 0.31 0.34 0.37 0.41 0.44
Accounts Receivable Turnover		 5.75 5.87 5.51 4.94 4.73 4.51 4.49 5.02 4.42 4.41 4.11
Inventory Turnover		 0.65 0.67 0.58 0.63 0.59 0.76 0.64 0.60 0.53 0.50 0.57
Fixed Asset Turnover		 1.45 1.49 1.55 1.62 1.74 1.82 1.79 1.99 2.26 2.71 3.23
Accounts Payable Turnover		 0.49 0.55 0.63 0.75 0.71 0.99 0.95 0.94 0.85 0.90 1.05
Days Sales Outstanding (DSO)		 63.46 62.13 66.22 73.92 77.11 81.00 81.23 72.68 82.61 82.76 88.88
Days Inventory Outstanding (DIO)		 565.64 545.71 627.16 582.73 614.90 479.97 572.20 606.16 686.44 735.94 643.96
Days Payable Outstanding (DPO)		 749.60 664.30 583.03 485.80 511.71 370.09 384.31 388.65 430.85 405.78 347.48
Cash Conversion Cycle (CCC)		 -120.50 -56.45 110.36 170.84 180.30 190.88 269.12 290.19 338.20 412.92 385.36
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,098 2,133 2,255 2,564 2,805 3,830 3,871 4,077 4,354 4,594 4,631
Invested Capital Turnover		 0.55 0.53 0.60 0.62 0.63 0.56 0.48 0.53 0.57 0.64 0.70
Increase / (Decrease) in Invested Capital		 966 36 122 309 241 1,026 41 205 277 241 37
Enterprise Value (EV)		 16,590 13,615 15,107 14,758 14,870 15,643 15,826 18,707 17,564 11,463 9,962
Market Capitalization		 16,893 14,247 15,660 15,162 15,187 15,918 16,220 19,234 18,162 12,527 11,417
Book Value per Share		 $14.89 $16.08 $15.99 $16.67 $17.38 $22.62 $23.23 $24.77 $26.29 $29.69 $31.68
Tangible Book Value per Share		 $9.43 $11.72 $11.92 $12.80 $13.74 $19.24 $20.05 $21.89 $23.68 $27.32 $29.55
Total Capital		 3,116 3,496 4,037 3,884 3,971 5,181 5,393 5,702 6,039 6,253 6,684
Total Debt		 715 730 1,228 916 848 1,075 1,127 1,099 1,087 595 597
Total Long-Term Debt		 662 661 814 830 486 1,075 1,079 1,083 593 595 597
Net Debt		 -303 -633 -554 -404 -318 -276 -394 -526 -598 -1,064 -1,456
Capital Expenditures (CapEx)		 228 148 199 145 145 114 96 121 97 85 103
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 105 262 409 535 618 784 762 887 1,199 1,488 1,634
Debt-free Net Working Capital (DFNWC)		 697 1,051 1,805 1,619 1,372 1,850 1,776 2,178 2,273 2,625 3,194
Net Working Capital (NWC)		 644 982 1,391 1,533 1,010 1,850 1,728 2,163 1,779 2,625 3,194
Net Nonoperating Expense (NNE)		 94 68 107 -9.26 -46 -884 6.44 11 -2.48 -45 -53
Net Nonoperating Obligations (NNO)		 -303 -633 -554 -404 -318 -276 -394 -526 -598 -1,064 -1,456
Total Depreciation and Amortization (D&A)		 78 128 123 127 117 122 117 109 99 91 77
Debt-free, Cash-free Net Working Capital to Revenue		 11.74% 23.42% 31.15% 35.85% 36.25% 42.16% 41.29% 42.32% 49.57% 52.13% 50.72%
Debt-free Net Working Capital to Revenue		 78.34% 94.13% 137.42% 108.56% 80.49% 99.42% 96.20% 103.93% 93.95% 91.99% 99.17%
Net Working Capital to Revenue		 72.39% 87.97% 105.86% 102.80% 59.25% 99.42% 93.59% 103.17% 73.54% 91.99% 99.17%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.07) ($3.80) ($0.67) ($0.44) ($0.13) $4.75 ($0.35) $0.76 $0.89 $2.25 $1.82
Adjusted Weighted Average Basic Shares Outstanding		 161.59M 165.99M 174.43M 177.06M 179.04M 180.80M 182.85M 185.27M 187.83M 190.03M 191.79M
Adjusted Diluted Earnings per Share		 ($1.07) ($3.81) ($0.67) ($0.44) ($0.13) $4.53 ($0.35) $0.75 $0.87 $2.21 $1.80
Adjusted Weighted Average Diluted Shares Outstanding		 161.59M 166.22M 174.43M 177.27M 179.04M 191.68M 182.85M 188.96M 191.60M 196.71M 197.39M
Adjusted Basic & Diluted Earnings per Share		 ($1.07) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 160.03M 172.87M 176.07M 178.37M 359.85M 181.83M 184.03M 186.53M 188.68M 190.78M 192.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -197 -143 -98 -121 -88 -67 -58 50 165 374 296
Normalized NOPAT Margin		 -22.14% -12.81% -7.44% -8.15% -5.15% -3.62% -3.12% 2.39% 6.83% 13.09% 9.19%
Pre Tax Income Margin		 -17.39% -74.41% -2.73% -9.57% -5.56% -2.63% -4.08% 7.14% 7.79% 18.98% 14.98%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.14 -20.22 -0.16 -2.78 -4.01 -1.24 -4.60 9.24 8.51 37.86 38.40
NOPAT to Interest Expense		 -2.03 -14.24 -0.24 -1.98 -3.00 -1.04 -3.76 9.54 9.53 30.12 27.17
EBIT Less CapEx to Interest Expense		 -9.09 -23.97 -4.82 -6.09 -10.19 -5.14 -10.83 1.66 2.93 31.12 28.94
NOPAT Less CapEx to Interest Expense		 -7.98 -17.99 -4.91 -5.29 -9.18 -4.94 -9.99 1.97 3.95 23.38 17.71
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 5.85% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioMarin Pharmaceutical

This table displays calculated financial ratios and metrics derived from BioMarin Pharmaceutical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 192,323,359.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 192,323,359.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.55
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 15.04% 20.22% 8.79% 19.61% 28.28% 15.65% 14.84% 15.92% 4.08% 17.03% 2.83%
EBITDA Growth		 123.62% 1,362.96% 56.18% 64.50% 152.63% 440.12% 110.53% 112.17% -117.09% -113.33% -36.03%
EBIT Growth		 1,435.79% 132.60% 84.94% 87.12% 301.76% 1,993.70% 147.34% 143.02% -134.85% -128.20% -39.80%
NOPAT Growth		 1,848.29% 413.90% 32.91% 88.28% 203.82% 313.38% 134.98% 128.86% -136.37% -126.27% -44.51%
Net Income Growth		 707.01% 8,282.73% 74.35% 91.25% 162.72% 513.22% 109.43% 124.43% -128.98% -137.28% -43.17%
EPS Growth		 625.00% 900.00% 70.37% 89.66% 161.90% 550.00% 106.52% 123.64% -129.09% -133.85% -43.16%
Operating Cash Flow Growth		 -14.32% 305.00% 163.53% 69.51% 63.28% 575.42% 271.28% 56.00% 66.46% -46.32% 26.52%
Free Cash Flow Firm Growth		 -31.11% -15.62% 4.54% -11.71% 52.69% 50.93% 134.83% 172.88% -53.98% 43.84% -1,304.19%
Invested Capital Growth		 6.85% 6.79% 5.75% 6.56% 4.79% 5.53% 2.57% 1.93% 3.26% 0.81% 17.57%
Revenue Q/Q Growth		 -2.34% 11.16% 0.41% 9.74% 4.73% 0.21% -0.29% 10.77% -5.97% 12.68% -12.39%
EBITDA Q/Q Growth		 -36.76% -39.61% 252.50% 22.18% -2.88% 29.12% 37.40% 23.13% -107.82% -0.68% 759.50%
EBIT Q/Q Growth		 -52.05% -75.15% 1,115.68% 29.19% 2.96% 29.47% 43.62% 26.94% -114.77% -4.77% 406.53%
NOPAT Q/Q Growth		 -43.00% -2.78% 1,478.33% 31.47% -8.02% 32.28% 46.88% 28.05% -114.62% 4.46% 410.26%
Net Income Q/Q Growth		 -27.95% -49.54% 335.15% 20.88% -1.02% 17.78% 48.62% 29.54% -112.78% -51.49% 326.58%
EPS Q/Q Growth		 -27.59% -52.38% 360.00% 19.57% 0.00% 18.18% 46.15% 29.47% -113.01% -37.50% 345.45%
Operating Cash Flow Q/Q Growth		 93.61% -79.74% 70.91% 152.84% 86.49% -16.19% -6.05% 6.24% 99.00% -72.97% 121.44%
Free Cash Flow Firm Q/Q Growth		 -48.92% -0.57% 37.53% -8.84% 36.93% -4.31% 148.64% 127.74% -233.25% 61.95% -942.93%
Invested Capital Q/Q Growth		 -0.05% 1.03% 3.24% 2.21% -1.70% 1.74% 0.35% 1.57% -0.43% -0.67% 17.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.97% 78.66% 80.71% 81.68% 74.73% 81.78% 79.66% 81.82% 81.95% 68.47% 74.55%
EBITDA Margin		 9.34% 5.07% 17.81% 19.83% 18.39% 23.70% 32.65% 36.30% -3.02% -2.70% 20.31%
Operating Margin		 5.25% 4.22% 13.63% 16.92% 15.27% 21.60% 30.05% 33.55% -6.02% -5.10% 16.92%
EBIT Margin		 5.11% 1.14% 13.83% 16.28% 16.01% 20.68% 29.78% 34.13% -5.36% -4.98% 17.44%
Profit (Net Income) Margin		 6.95% 3.15% 13.66% 15.05% 14.22% 16.72% 24.92% 29.14% -3.96% -5.33% 13.77%
Tax Burden Percent		 96.90% 105.42% 84.00% 81.11% 78.90% 73.65% 77.99% 80.75% 116.79% 171.52% 74.73%
Interest Burden Percent		 140.26% 261.85% 117.63% 113.98% 112.64% 109.77% 107.28% 105.73% 63.28% 62.30% 105.69%
Effective Tax Rate		 3.10% -5.42% 16.00% 18.89% 21.10% 26.35% 22.01% 19.25% 0.00% 0.00% 25.27%
Return on Invested Capital (ROIC)		 2.82% 2.55% 6.47% 7.98% 7.52% 10.15% 15.19% 17.89% -2.84% -2.49% 8.18%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.90% 4.05% 3.57% 6.35% 5.34% 9.42% 13.93% 16.23% -3.01% -1.28% 7.30%
Return on Net Nonoperating Assets (RNNOA)		 -0.11% -0.48% -0.36% -0.73% -0.77% -1.48% -2.26% -2.92% 0.60% 0.27% -1.20%
Return on Equity (ROE)		 2.71% 2.08% 6.11% 7.24% 6.75% 8.67% 12.93% 14.97% -2.24% -2.22% 6.97%
Cash Return on Invested Capital (CROIC)		 -3.51% -2.65% -1.94% -1.74% 1.33% 3.15% 8.04% 11.18% 7.07% 5.61% -11.77%
Operating Return on Assets (OROA)		 1.81% 0.42% 5.14% 6.18% 6.47% 8.53% 12.54% 14.40% -2.29% -2.20% 7.18%
Return on Assets (ROA)		 2.46% 1.15% 5.08% 5.72% 5.75% 6.90% 10.49% 12.29% -1.69% -2.35% 5.67%
Return on Common Equity (ROCE)		 2.71% 2.08% 6.11% 7.24% 6.75% 8.67% 12.93% 14.97% -2.24% -2.22% 6.97%
Return on Equity Simple (ROE_SIMPLE)		 3.00% 0.00% 4.05% 4.85% 5.95% 0.00% 9.04% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 30 29 74 98 90 119 175 224 -33 -31 97
NOPAT Margin		 5.09% 4.45% 11.45% 13.72% 12.05% 15.91% 23.43% 27.09% -4.21% -3.57% 12.64%
Net Nonoperating Expense Percent (NNEP)		 1.92% -1.49% 2.91% 1.63% 2.18% 0.73% 1.26% 1.66% 0.17% -1.22% 0.87%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.48% - - - 1.90% 2.73% 3.38% -0.49% -0.47% 1.27%
Cost of Revenue to Revenue		 22.03% 21.34% 19.29% 18.32% 25.27% 18.22% 20.34% 18.18% 18.05% 31.53% 25.45%
SG&A Expenses to Revenue		 37.12% 40.16% 34.82% 36.94% 33.99% 35.68% 27.66% 28.14% 34.58% 51.02% 33.71%
R&D to Revenue		 32.91% 31.92% 31.59% 25.81% 24.79% 23.22% 21.30% 19.54% 52.76% 22.00% 23.34%
Operating Expenses to Revenue		 72.72% 74.43% 67.07% 64.76% 59.46% 60.18% 49.61% 48.27% 87.97% 73.58% 57.63%
Earnings before Interest and Taxes (EBIT)		 30 7.38 90 116 119 155 222 282 -42 -44 134
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 54 33 116 141 137 177 243 300 -23 -24 156
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.40 3.67 3.24 2.96 2.47 2.21 2.33 1.75 1.72 1.88 1.75
Price to Tangible Book Value (P/TBV)		 3.79 4.07 3.58 3.24 2.70 2.41 2.52 1.89 1.85 2.01 1.87
Price to Revenue (P/Rev)		 7.21 7.51 6.66 6.04 4.86 4.39 4.57 3.44 3.36 3.54 3.35
Price to Earnings (P/E)		 113.25 108.34 80.08 60.93 41.52 29.35 25.74 16.04 19.98 32.72 40.43
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.88% 0.92% 1.25% 1.64% 2.41% 3.41% 3.88% 6.23% 5.00% 3.06% 2.47%
Enterprise Value to Invested Capital (EV/IC)		 3.73 4.03 3.53 3.25 2.76 2.50 2.67 1.96 1.93 2.15 1.86
Enterprise Value to Revenue (EV/Rev)		 6.95 7.26 6.42 5.77 4.54 4.02 4.17 3.00 2.91 3.09 3.11
Enterprise Value to EBITDA (EV/EBITDA)		 74.24 71.14 55.02 43.45 29.26 20.08 17.61 10.73 12.93 20.09 24.68
Enterprise Value to EBIT (EV/EBIT)		 136.65 119.03 84.09 61.55 37.56 23.90 20.11 11.83 14.61 23.80 30.51
Enterprise Value to NOPAT (EV/NOPAT)		 123.67 106.34 99.58 72.75 47.03 30.05 25.56 15.15 19.10 33.64 45.85
Enterprise Value to Operating Cash Flow (EV/OCF)		 115.92 110.29 56.66 45.43 30.10 20.01 17.57 11.99 9.85 12.03 11.52
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 212.00 81.35 33.61 17.74 27.75 38.47 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.22 0.22 0.21 0.21 0.11 0.11 0.10 0.10 0.10 0.10 0.23
Long-Term Debt to Equity		 0.12 0.12 0.12 0.11 0.11 0.11 0.10 0.10 0.10 0.10 0.23
Financial Leverage		 -0.12 -0.12 -0.10 -0.12 -0.14 -0.16 -0.16 -0.18 -0.20 -0.21 -0.16
Leverage Ratio		 1.38 1.38 1.37 1.35 1.32 1.30 1.29 1.28 1.26 1.24 1.31
Compound Leverage Factor		 1.93 3.62 1.61 1.54 1.49 1.43 1.38 1.36 0.80 0.77 1.39
Debt to Total Capital		 18.15% 18.00% 17.66% 17.08% 9.90% 9.52% 9.32% 9.00% 8.97% 8.93% 18.72%
Short-Term Debt to Total Capital		 8.25% 8.18% 8.02% 7.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.90% 9.82% 9.63% 9.32% 9.90% 9.52% 9.32% 9.00% 8.97% 8.93% 18.72%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 81.85% 82.00% 82.34% 82.92% 90.10% 90.48% 90.68% 91.00% 91.03% 91.07% 81.28%
Debt to EBITDA		 5.02 4.40 3.77 3.17 1.39 1.04 0.85 0.70 0.86 1.20 3.50
Net Debt to EBITDA		 -2.72 -2.42 -2.01 -2.01 -2.10 -1.86 -1.69 -1.57 -2.00 -2.94 -1.94
Long-Term Debt to EBITDA		 2.74 2.40 2.06 1.73 1.39 1.04 0.85 0.70 0.86 1.20 3.50
Debt to NOPAT		 8.36 6.58 6.83 5.30 2.24 1.56 1.24 0.98 1.27 2.02 6.51
Net Debt to NOPAT		 -4.53 -3.62 -3.63 -3.37 -3.38 -2.79 -2.46 -2.21 -2.96 -4.92 -3.61
Long-Term Debt to NOPAT		 4.56 3.59 3.72 2.89 2.24 1.56 1.24 0.98 1.27 2.02 6.51
Altman Z-Score		 5.91 6.31 6.11 5.98 6.39 6.54 6.97 5.51 4.91 5.48 3.74
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.54 2.51 2.74 3.05 4.27 5.33 5.52 5.56 4.83 5.21 5.81
Quick Ratio		 1.46 1.45 1.55 1.79 2.39 2.96 3.20 3.34 2.84 3.25 3.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -247 -248 -170 -185 -117 -122 59 135 -180 -68 -713
Operating Cash Flow to CapEx		 624.09% 95.04% 179.94% 556.86% 1,199.59% 950.47% 1,040.04% 1,083.39% 1,296.04% 244.69% 1,054.59%
Free Cash Flow to Firm to Interest Expense		 -65.28 -40.68 -47.93 -51.77 -39.32 -47.24 20.68 50.34 -69.67 -24.61 -47.67
Operating Cash Flow to Interest Expense		 35.89 4.51 13.24 33.23 74.62 72.03 60.91 69.16 142.96 35.87 14.75
Operating Cash Flow Less CapEx to Interest Expense		 30.14 -0.24 5.88 27.26 68.40 64.45 55.06 62.77 131.93 21.21 13.35
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.35 0.37 0.37 0.38 0.40 0.41 0.42 0.42 0.43 0.44 0.41
Accounts Receivable Turnover		 4.66 4.42 4.00 3.98 4.08 4.41 4.29 3.96 3.95 4.11 3.95
Inventory Turnover		 0.56 0.53 0.49 0.47 0.51 0.50 0.50 0.50 0.45 0.57 0.60
Fixed Asset Turnover		 2.18 2.26 2.32 2.44 2.61 2.71 2.82 2.94 2.97 3.23 3.26
Accounts Payable Turnover		 0.90 0.85 0.85 0.86 0.82 0.90 0.99 1.00 0.76 1.05 1.07
Days Sales Outstanding (DSO)		 78.36 82.61 91.19 91.76 89.50 82.76 85.14 92.16 92.48 88.88 92.48
Days Inventory Outstanding (DIO)		 655.07 686.44 743.98 781.22 714.56 735.94 725.90 735.48 808.96 643.96 611.16
Days Payable Outstanding (DPO)		 406.89 430.85 431.06 423.23 447.67 405.78 367.57 366.24 478.17 347.48 340.92
Cash Conversion Cycle (CCC)		 326.54 338.20 404.11 449.75 356.40 412.92 443.48 461.40 423.27 385.36 362.73
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4,309 4,354 4,495 4,594 4,516 4,594 4,610 4,683 4,663 4,631 5,420
Invested Capital Turnover		 0.55 0.57 0.57 0.58 0.62 0.64 0.65 0.66 0.67 0.70 0.65
Increase / (Decrease) in Invested Capital		 276 277 244 283 207 241 115 89 147 37 810
Enterprise Value (EV)		 16,062 17,564 15,873 14,940 12,484 11,463 12,303 9,197 9,005 9,962 10,072
Market Capitalization		 16,650 18,162 16,452 15,633 13,382 12,527 13,486 10,542 10,400 11,417 10,864
Book Value per Share		 $26.02 $26.29 $26.86 $27.84 $28.43 $29.69 $30.37 $31.43 $31.54 $31.68 $32.30
Tangible Book Value per Share		 $23.37 $23.68 $24.35 $25.41 $26.03 $27.32 $28.04 $29.16 $29.31 $29.55 $30.22
Total Capital		 5,983 6,039 6,162 6,375 6,008 6,253 6,389 6,623 6,653 6,684 7,642
Total Debt		 1,086 1,087 1,088 1,089 595 595 596 596 597 597 1,430
Total Long-Term Debt		 593 593 594 594 595 595 596 596 597 597 1,430
Net Debt		 -588 -598 -579 -692 -898 -1,064 -1,183 -1,345 -1,394 -1,456 -792
Capital Expenditures (CapEx)		 22 29 26 21 18 20 17 17 28 41 21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,160 1,199 1,345 1,463 1,410 1,488 1,567 1,689 1,578 1,634 1,589
Debt-free Net Working Capital (DFNWC)		 2,285 2,273 2,391 2,687 2,341 2,625 2,840 3,121 3,056 3,194 3,812
Net Working Capital (NWC)		 1,792 1,779 1,897 2,192 2,341 2,625 2,840 3,121 3,056 3,194 3,812
Net Nonoperating Expense (NNE)		 -11 8.38 -14 -9.48 -16 -6.06 -11 -17 -1.94 15 -8.64
Net Nonoperating Obligations (NNO)		 -588 -598 -579 -692 -898 -1,064 -1,183 -1,345 -1,394 -1,456 -792
Total Depreciation and Amortization (D&A)		 25 25 26 25 18 23 21 18 18 20 22
Debt-free, Cash-free Net Working Capital to Revenue		 50.19% 49.57% 54.41% 56.51% 51.24% 52.13% 53.13% 55.13% 51.01% 50.72% 49.02%
Debt-free Net Working Capital to Revenue		 98.91% 93.95% 96.76% 103.81% 85.04% 91.99% 96.25% 101.88% 98.78% 99.17% 117.57%
Net Working Capital to Revenue		 77.56% 73.54% 76.76% 84.70% 85.04% 91.99% 96.25% 101.88% 98.78% 99.17% 117.57%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.21 $0.11 $0.47 $0.56 $0.56 $0.66 $0.97 $1.25 ($0.16) ($0.24) $0.55
Adjusted Weighted Average Basic Shares Outstanding		 188.22M 187.83M 188.87M 190.11M 190.43M 190.03M 190.97M 191.91M 192.03M 191.79M 192.50M
Adjusted Diluted Earnings per Share		 $0.21 $0.10 $0.46 $0.55 $0.55 $0.65 $0.95 $1.23 ($0.16) ($0.22) $0.54
Adjusted Weighted Average Diluted Shares Outstanding		 191.17M 191.60M 199.26M 200.51M 197.15M 196.71M 196.47M 197.09M 192.03M 197.39M 197.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 188.37M 188.68M 189.88M 190.38M 190.58M 190.78M 191.78M 192.01M 192.11M 192.32M 193.28M
Normalized Net Operating Profit after Tax (NOPAT)		 30 19 66 98 90 119 175 224 -33 -31 97
Normalized NOPAT Margin		 5.09% 2.96% 10.16% 13.72% 12.05% 15.91% 23.43% 27.09% -4.21% -3.57% 12.64%
Pre Tax Income Margin		 7.17% 2.99% 16.27% 18.56% 18.03% 22.70% 31.95% 36.09% -3.39% -3.10% 18.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 7.86 1.21 25.30 32.44 40.21 59.97 77.52 105.16 -16.13 -15.69 8.93
NOPAT to Interest Expense		 7.83 4.72 20.95 27.34 30.28 46.13 60.99 83.46 -12.67 -11.24 6.48
EBIT Less CapEx to Interest Expense		 2.11 -3.53 17.94 26.47 33.99 52.39 71.66 98.78 -27.16 -30.35 7.53
NOPAT Less CapEx to Interest Expense		 2.08 -0.03 13.59 21.37 24.06 38.55 55.13 77.08 -23.70 -25.90 5.08
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

BioMarin’s latest four quarters show growing top-line momentum in 2025, solid cash generation, and a strong balance sheet, but profitability has been volatile with losses in the latter part of the year and meaningful investing activity.

  • Revenue rose to $874.6 million in Q4 2025, up from $747.3 million in Q4 2024 (roughly a 17% year-over-year increase), indicating improving topline momentum.
  • Operating cash flow from continuing activities was strong in 2025, highlighted by about $368.7 million in Q3 2025, with other quarters also delivering positive cash from operations, supporting liquidity.
  • Two consecutive profitable quarters earlier in 2025: net income attributable to common shareholders was approximately $88.7 million in Q1 2025 and $240.5 million in Q2 2025, showing meaningful quarterly profitability at times during the year.
  • Balance sheet remains solid, with total equity around $6.06B and total assets about $7.61B as of 2025-Q3, while liabilities are relatively moderate (around $1.56B).
  • Free cash flow potential shown in Q3 2025: roughly $368.7 million of operating cash flow minus about $28.4 million in capex implies substantial quarterly free cash flow can be generated when operations are strongest.
  • Gross margin has varied, with Q4 2025 gross margin about 68.5% (598.9M gross profit on 874.6M revenue) versus higher margins in earlier quarters, suggesting quarterly mix effects or one-off items.
  • R&D and SG&A remain elevated (e.g., R&D around $192.4M and SG&A around $446.2M in Q4 2025), reflecting ongoing pipeline investments that press on near-term profitability.
  • Profitability remains volatile: net income attributable to common shareholders shrank to negative in Q3 2025 and again in Q4 2025 (approximately -$30.7M and -$46.6M, respectively).
  • Investing cash outflows were substantial in 2025, including a large spend in Q3 2025 of about $-330.96M (acquisitions and investments) and continued outflows in Q4 2025, which could pressure near-term liquidity and capex capacity.
  • Operating income turned negative in Q4 2025 (-$44.61M) despite earlier quarters’ improvements, underscoring ongoing earnings volatility and the challenge of achieving consistent profitability.
05/17/26 06:42 AM ETAI Generated. May Contain Errors.

BioMarin Pharmaceutical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioMarin Pharmaceutical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BioMarin Pharmaceutical's net income appears to be on an upward trend, with a most recent value of $348.90 million in 2025, falling from -$171.80 million in 2015. The previous period was $426.86 million in 2024. See where experts think BioMarin Pharmaceutical is headed by visiting BioMarin Pharmaceutical's forecast page.

BioMarin Pharmaceutical's total operating income in 2025 was $409.48 million, based on the following breakdown:
  • Total Gross Profit: $2.50 billion
  • Total Operating Expenses: $2.09 billion

Over the last 10 years, BioMarin Pharmaceutical's total revenue changed from $889.90 million in 2015 to $3.22 billion in 2025, a change of 262.0%.

BioMarin Pharmaceutical's total liabilities were at $1.51 billion at the end of 2025, a 13.2% increase from 2024, and a 13.4% increase since 2015.

In the past 10 years, BioMarin Pharmaceutical's cash and equivalents has ranged from $397.04 million in 2015 to $1.31 billion in 2025, and is currently $1.31 billion as of their latest financial filing in 2025.

Over the last 10 years, BioMarin Pharmaceutical's book value per share changed from 14.89 in 2015 to 31.68 in 2025, a change of 112.8%.


Related Companies

Financial statements for NASDAQ:BMRN last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel